Armistice Capital Reports New 9.99% Stake in Evogene Ltd. (EVGN)

On May 15, 2026, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G disclosing a significant new position in Evogene Ltd. (EVGN). As of the event date of March 31, 2026, the reporting persons beneficially own 1,104,906 ordinary shares, representing a 9.99% ownership stake in the company. The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. Under an Investment Management Agreement, Armistice Capital exercises shared voting and dispositive power over the securities. Steven Boyd, as the managing member of Armistice Capital, is also deemed to have shared beneficial ownership. The filing indicates that these shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This filing marks a notable entry for the investment firm into Evogene Ltd., a biotechnology company based in Israel.